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Abstract Glucocorticoids (GC) represent the main treatment
for pemphigus; however, some patients show GC resistance.
GC sensitivity was evaluated in 19 pemphigus patients and 41
controls by the number of binding sites [Bmax (fmol/mg pro-
tein)] and the affinity of GC receptor [Kd (nM)] to dexameth-
asone (DEX) as well as by the pattern of cytokine by DEX-
mediated inhibition of concanavalin-A (Con-A)-stimulated
PBMC proliferation. The Kd (15.7±2.8 vs.8.1±1.3) and Bmax
(6.5±0.9 vs. 3.9±0.3) were higher in pemphigus than controls
(p00.002). Considering the values above the 95th percentile
of normal group as a cut-off (Kd>24.9 nM and Bmax>8.1
fmol/mg protein), elevated Kd and Bmax were observed in
9.8% and 2.4% of controls and 15.8% and 36.8% of patients
(p00.02). PBMC proliferation was stimulated by Con-A and
inhibited by DEX (p<0.001) in both pemphigus and control
groups. IL-6 and TNFα (pg/mL) basal production were higher
in patients than controls. There was an increment of these
cytokines after Con-A stimulation, and they were inhibited by
DEX (p00.002) in controls and remained elevated in pemphi-
gus (p<0.02). Patients and controls showed no difference in
basal and stimulated production of IL-8 and IL-10. There is an
alteration on GC sensitivity in pemphigus patients and a higher
production of proinflammatory cytokines. Therefore, in pem-
phigus patients, proinflammatory cytokines might be involved
in the mechanism of GC resistance and/or in its maintenance.
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Introduction
Pemphigus is an autoimmune blistering disease of the skin,
which is characterized both histologically by cell/cell detach-
ment of epidermal cells (acantholysis), and immunologically,
by binding of autoantibodies to the adhesion molecules of
keratinocytes, such as to desmogleins (Dsg) of epidermal cells
besides other molecules [1]. Twomajor forms of the disease are
recognized, as defined by clinical and histological findings.
Pemphigus vulgaris (PV) affects the skin and mucous mem-
brane and causes histologically acantholysis in the deep epi-
dermis, primarily suprajacent to the basal cells. Pemphigus
foliaceus (PF) usually affects the skin and generates acanthol-
ysis at the level of granular cells, forming blisters in the
superficial epidermis [2]. The target antigens for the pemphigus
autoantibodies have been shown to be localized at desmosomal
junctions of epidermis which are transmembrane proteins from
the cadherins family by immunoelectron microscopy. Bio-
chemical and molecular genetic studies defined Dsg-3
(130 kDa) as the main autoantibody for PV [3, 4] and Dsg1
(160 kDa) for PF and PV [5, 6]. The stages of the evolution of
pemphigus, its treatment, and the definition of therapy failure
were recently defined by an international consensus [7].
Brazil is considered an endemic region for PF and the
epidemiological factors might differ from European PF [8].
The pathophisiological mechanisms of acantholysis in endem-
ic PF remain unclear despite of several studies [9–11]. While
pemphigus is an antibody mediated disease, the role of T cells
in its pathogenesis is being increasingly recognized [12]. T
cells from pemphigus patients recognize desmoglein antigen
and can influence the role of the cytokines on the clinical
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course of the disease. Indeed, a high production of cytokines
involved in the inflammatory response, such as interleukin 1
(IL-1) and tumor necrosis factor α (TNF-α), has been dem-
onstrated in blood cells from PF and PV patients, while
increased serum IL-6 production has been correlated to the
disease activity in PV [13, 14]. In addition, previous studies
observed that CD56+ CD3– natural killer cells (NK) were
increased in patients with active PV, suggesting that NK cells
contribute to Th2-based immune responses through IL-12Rb2
signaling impairment and up-regulation of IL-5 and Il-10 [15].
It has been also suggested that cellular and molecular interac-
tion of the combination of NK, CD4+ T cells and Dsg1 and 3
influences the microenvironment of the skin and mucosal
tissues during the preclinical and subsequent clinical stages
[16]. Therefore, current information has been associated NK
cells in the pathogenesis of blistering diseases, including
pemphigus vulgaris patients [17].
The prognosis of PF is usually more favorable in PV than
in PF; in both types it has been improved considerably since
the introduction of corticosteroids [18]. Glucocorticoids
(GCs) affect a variety of important functions throughout the
body, such as glucose and fat metabolism, mediate stress
response, influence the immune and central nervous system
activity and have numerous effects on development and cell
differentiation. Regulation of serum GC concentrations is
under the influence of the hypothalamus-pituitary-adrenal
(HPA) axis and circulating GCs themselves exert a negative
feedback on both hypothalamic and the pituitary levels. GCs
act via the cytoplasmic glucocorticoid receptor (GR), which is
a member of the nuclear receptor family [19]. GR precursor
mRNA is processed into at least two alternative splice products,
hGRα and a nonligand-binding isoform, hGRβ, which acts as
a dominant negative inhibitor of hGRα on glucocorticoid-
responsive promoters [20, 21]. GC act by binding to a cyto-
plasmic GR, which then translocates to the nucleus to act as a
transcription factor [19].
Current treatment regimens for pemphigus use high-dose
systemic GC; unfortunately, the high doses and prolonged
administration of corticosteroids that are often needed to con-
trol the disease result in numerous side effects, many of which
are serious or even life-threatening [18]. However, some
patients do not respond to GC regimen [22]. In an attempt to
identify predictive factors of the response to GC, the pattern of
dexamethasone (DEX) mediated inhibition of Concanavalin-
A (Con-A) stimulated peripheral blood mononuclear cells
(PBMC) proliferation has been used in different inflammatory
and immune disease as asthma [23], rheumatoid arthritis [24],
idiopatic nephrotic syndrome [25], patients awaiting renal
transplantation [26]. These studies have demonstrated an in-
creased lymphocyte resistance to the effects of GC in these
disorders. In a recent study, we observed similar finding also
in healthy subjects [27]. In addition, previous studies have
demonstrated diminished GC receptor number and affinity in
PBMC from rheumatoid arthritis [28] and asthma steroid-
resistant patients [29]. It is important to point out that some
GC alterations, such as an increased number of GR per cell,
can be reversible in culture medium alone but sustained with
the co-incubation of IL-2 and IL-4, suggesting that inflamma-
tion and cytokine secretionmay also contribute to the acquired
GC receptor defect found in asthma steroid resistant. Indeed, a
disturbed immune regulation contributes to the corticosteroid
resistance in some diseases [23, 24, 30].
There are no studies on GC sensitivity in pemphigus
patients. In this study, we hypothesized that cytokines could
differentially regulate the sensitivity of PBMC to GC in pem-
phigus patients. Taking advantages of different bioassays per-
formed on the same subject, we evaluated the number and
affinity of GC receptor, the DEXmediated inhibition of Con-A
stimulated PBMC proliferation and cytokine profile in patients
with pemphigus. We observed an alteration on GC sensitivity
in untreated pemphigus patients. In addition, PBMC from
pemphigus patients showed a higher production of proinflam-
matory cytokines, which were only partially inhibited even
when higher GC doses were used. All these evidences suggest
that proinflammatory cytokines could play an important role in
the immunopathogenesis of pemphigus and might be involved
in the mechanism of GC resistance or in the maintenance of
this phenomenon in pemphigus patients.
Material and Methods
Subjects
This prospective study was approved by the institutional re-
view board for human research of School of Medicine of
Ribeirão Preto - University of São Paulo and informed consent
in written formwas obtained from all subjects and their parents.
We studied 19 patients with pemphigus followed at Derma-
tology Clinic of the University Hospital, Faculty ofMedicine of
Ribeirão Preto, University of São Paulo, Brazil. The diagnosis
of PF and PVwere confirmed by the histopathological findings
and by direct immunofluorescence. Patients with predominant
erosions and crusts on the head and upper thorax were consid-
ered to have localized PF. Patients with PV presented erosions
in oral and or genital mucosal regions and flaccid bullous
spread throughout the tegument. At the time of the study,
patients with pemphigus had never been treated for or were
off corticosteroid therapy for at least consecutive 30 days in-
terval. Clinical findings, localization of lesions, classification of
pemphigus, previous treatment, and diagnostic confirmation by
direct immunofluorescence can be seen in the Table 1.
CG sensitivity evaluated by the number of binding sites
(Bmax) and the affinity of glucocorticoid receptor (Kd) by
hormone binding assay and also the pattern of dexamethasone-
mediated inhibition of concanavalin-A (Con-A)-stimulated
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peripheral blood mononuclear cells (PBMC) proliferation using
different doses of DEX had been previously evaluated in 41con-
trol subjects (21 F, 20 M; 22–62 years old) [27]. In the present
study, using both methods, we performed CG sensitivity analy-
sis in 19 pemphigus patients (11 F, 8 M; 16–63 years old; PF0
12 and PV07). In addition, in all these patients as well as in six
healthy controls (4 F, 2 M; 32–63 years old), we also evaluated
the IL-6, IL-8, IL-10 and TNF-α secretion in medium culture of
PBMC in basal condition and after treatment with Con-A alone
or associate with different doses (10−10 to 10−4 M) of DEX.
Cell Preparation
PBMC were isolated by density gradient centrifugation using
Ficoll-Hypaque (Histopaque-Sigma Chemical Co, St Louis,
MO), washed three times in Hanks buffered saline solution
and resuspended in RPMI 1640 (Life Technologies, Gaithers-
burg, MD) containing 2 mM HEPES buffer (Sigma Chemical
Co, St Louis,MO), 10% fetal calf serum, 100 IUml−1 penicillin,
100 gml−1 streptomycin and 10 mg ml−1 gentamicin.
Binding Assay
PBMC DEX-binding assay was performed as previously de-
scribed [25–27]. Cells were suspended in RPMI media and
adjusted to 2×106 cells per tube in duplicate and incubated
with six concentrations (1.56–50 nM) of DEX ([1,2,4,6,7-3H]
Dexamethasone, Amersham Life Science, England) at 37°C
in the presence or absence of a 1.000-fold molar excess of
unlabeled DEX (Dexamethasone Sigma, St Louis, MO, USA)
for 1 h. After incubation, the cells were washed three times to
separate bound from free steroid with 1.5 ml cold PBS and
centrifuged at 400 × g for 10 min. After the third wash, the
pellets were suspended in 100 μl of RPMI, transferred to vials
and the radioactivity was counted in a β-counter. Specific
binding was calculated by subtracting non-specific binding
from total binding. Receptor assay data were analyzed by the
method of Scatchard using computerized linear regression
analysis. The binding capacity (Bmax) was expressed as fmol
of dexamethasone bound per mg of protein, and the dissoci-
ation constant (Kd), inversely proportional to ligand affinity,
was expressed in nM.
Proliferation and in vitro corticosteroid sensitivity assay
To perform the in vitro steroid sensitivity assay we measured
the inhibitory effect of DEX on Con-A-stimulated PBMC
proliferation. PBMC (2×10−6 cells per well) were plated onto
96-well flat-bottomed plates (Nunc, Denmark) in triplicate
and cultured at 37°C in the presence of 5% CO2. Con-A at
the dose of 50 μg ml -1 was used to stimulate the cells in the
presence or absence of different doses (10−10, 10−9, 10−8,
10−7, 10−6, 10−5 and 10−4 M) of DEX. After 48 h of culture,
the cells were pulsed with 1 μCi/well tritiated thymidine (3H-
Table 1 Clinical findings in patients with pemphigus foliaceus and pemphigus vulgaris
Patients Sex Age (y) Type of
pemphigus
Clinical
compromising
Time of onset
of the disease
Previous systemic
t reatment
1 F 38 Foliaceus Localized form (seborheic areas) 14 y Prednisone plus dapsone
2 M 16 Foliaceus Generalized form 5 y No treatment
3 F 51 Foliaceus Localized form (seborheic areas) 6 y Prednisone plus azathioprine
4 F 30 Foliaceus Localized form (seborheic areas) 2 y Prednisone plus azathioprine
5 M 33 Foliaceus Localized form (seborheic areas) 3 y No treatment
6 F 28 Foliaceus Generalized form 1 y Prednisone
7 M 19 Foliaceus Generalized form 4 y Prednisone plus chloroquine
8 F 45 Foliaceus Generalized form 5 y Prednisone
9 M 34 Foliaceus Generalized form 1 y No treatment
10 F 44 Foliaceus Generalized form 12 y Prednisone
11 M 16 Foliaceus Generalized form 2 mo No treatment
12 F 41 Foliaceus Generalized form 10 mo No treatment
13 F 36 Vulgaris Vegetant variety with oral compromising 1 y No treatment
14 F 27 Vulgaris Generalized lesions with oral compromising 2 mo No treatment
15 M 44 Vulgaris Lesions on trunk with oral compromising 1 y Dapsone
16 F 16 Vulgaris Generalized lesions with oral compromising 1 mo No treatment
17 M 50 Vulgaris Generalized lesions with oral compromising 2 mo No treatment
18 M 50 Vulgaris Lesions on trunk with oral compromising 2 mo No treatment
19 F 63 Vulgaris Lesions on trunk with oral and genital compromising 1 y No treatment
F female; M male; y years; mo months
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thymidine, Amersham, Pharmacia Biotech, UK) for 18 h prior
to collecting the supernatants for cytokine quantification. The
cells were harvested with a multiple automated sample har-
vester and radioactivity was counted in a liquid scintillationβ-
counter (Beckman, Fullerton, CA). Percent inhibition of pro-
liferation by steroid was calculated using the following for-
mula: 1 x n=y nð Þf g100, where: x 0 counts in Dex and
Con-A; n 0 counts in RPMI alone, y 0 counts in Con-A alone.
The IC50 was defined as the concentration of DEX that caused
a 50% inhibition of cell proliferation.
Cytokine Quantification
The supernatants collected during cell culture were stored
at −70°C for measurement of IL-6, IL-8, IL-10, and TNF-α
levels by ELISA (BD OptEIA, BD Biosciences Pharmigen,
San Diego, CA). The minimum detection limits for IL-6, IL-8,
IL-10 and TNF-αwere 4.7, 3.1, 7.8 and 7.8 pg/ml, respectively.
Undetectable cytokine levels were considered as the minimum
detection limit of each assay.
Statistical Analysis
All results are expressed as the Mean ± SE. Data were com-
pared using One-Way ANOVA followed by Newman-Keuls
Multiple Comparison Test. Mann–Whitney test was used
when appropriate. Level of significance was set at p<0.05.
Results
Binding Assay
The linearity of the Scatchard plots indicates a single class of
binding site affinity. The Kd (nM) and Bmax (fmol/mg protein)
values were 8.1±1.3 and 3.9±0.3 in control and 15.7±2.8 and
6.5±0.9 in pemphigus patients. Patients with pemphigus had
Kd and Bmax values significantly higher than healthy subjects
(p00.002 and p00.0002, respectively). Considering the values
above the 95th percentile of the normal group (Kd >24.9 nM
and Bmax>8.1 fmol/mg of protein), 4 out of 41 controls (9.8%)
and 3 out of 20 (15.8%) pemphigus patients showed an elevat-
ed Kd (p00.02) while one out of 41 controls (2.4%) and 7 out
of 20 (36.8%) pemphigus patients showed an elevated Bmax
(p00.01). Figure 1 shows a representative saturation curve and
Scatchard plot of one individual with normal Kd and one
individual with an elevated Kd.
Proliferation Assays
Basal lymphocyte proliferation was stimulated by Con-A in
the control group (761±60.7 vs. 36866±2647 cpm; p<
0.001) and pemphigus patients (780±92 vs. 43089±
3360 cpm; p<0.001). There was no difference in lympho-
cyte proliferation on basal condition between the control
and pemphigus groups. Different doses of DEX (10−10,
10−8, 10−6, 10−4 M) inhibited lymphocyte proliferation in a
dose-dependent manner in both control and pemphigus
groups (Fig. 2). There was no difference in the IC50 between
controls and pemphigus patients.
Cytokines
Cytokine levels were measured in the supernatant collected
from fresh cultured PBMC in the basal condition and after
stimulation with Con-A alone or Con-A plus different doses
of Dex (10−10, 10−9, 10−8, 10−7, 10−6, 10−5 and 10−4 M) in
control subjects and pemphigus patients. PBMC from pem-
phigus patients showed IL-6 basal production higher than
controls (934.5±66.8 vs. 501.7±87.9 pg/mL; p00.005).
There was an increment of IL-6 secretion after Con-A stimu-
lation in both controls (1982±370.8 pg/mL; p00.009) and
pemphigus patients (2469±101 pg/mL; p00.0001), with no
difference between groups. IL-6 secretion was significantly
inhibited by DEX dose of 10−7 M in controls and pemphigus
patients (p00.01). However, in pemphigus patients the levels
of IL-6 remained elevated compared to controls (p00.01)
even after a high doses of Dex (10−4M). These data are shown
in Fig. 3a.
PBMC from pemphigus patients showed TNF-α basal pro-
duction higher than controls (77.7±12.1 vs. 7.8±2.1 pg/mL;
p00.002). There was an increment of TNF-α secretion after
Con-A stimulation in controls (560.5±146.3 pg/mL; p00.002)
and pemphigus patients (2031±218 pg/mL; p00.0001), how-
ever in the pemphigus group TNF-α secretion was higher than
controls (p00.001). TNF-α secretion was significantly
inhibited by DEX dose of 10−8 M in controls (p00.002) and
pemphigus patients (p00.0004). However, in pemphigus
patients the levels of TNF-α secretion remained elevated com-
pared to controls after all doses of DEX (p<0.02). These data
are shown in Fig. 3b.
IL-8 basal production of PBMC from pemphigus patients
(5713±309 pg/mL) showed no difference from controls
(5748±441 pg/mL). IL-10 basal production of PBMC from
pemphigus patients (90.5±19.3 pg/mL) also showed no
difference from controls (47.8±10.2 pg/mL). In pemphigus
patients, Con-A stimulated PBMC increased significantly
IL-8 (6857±187.4 pg/mL; p<0.0001) and IL-10 (1103±
78.7 pg/mL; p<0.0001) secretion compared to the basal
production. The same was observed in controls: IL-
8 (6741±284.6 pg/mL; p00.01) and IL-10 (1032±
118.6 pg/mL; p00.002). IL-8 and IL-10 secretion were
significantly inhibited by DEX dose of 10−7 M in pemphi-
gus patients (p00.0004) and in controls (p00.002). Data on
IL-8 and IL-10 secretion are shown in Fig. 3c and d,
respectively.
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Discussion
In the present study, taking advantages of two bioassays, the
binding assay andDEXmediated inhibition of concanavalin-A
(Con-A) stimulated PBMC proliferation, we observed that
pemphigus patients showed an increased number and a de-
creased affinity of GR to DEX compared to healthy subjects,
suggesting GC resistance in untreated pemphigus. In addition,
we demonstrated that the GC resistance observed in these
patients was associated with a proinflammatory cytokine
pattern.
Some recent reports have shown an increasing incidence of
pemphigus in UK and Brazil [31, 32]. The treatment regimen is
individualized based on the subtype of pemphigus, age of the
patient, severity and extent of the disease, and rate of disease
progression. Local applications of steroids, including creams,
gels, and swishes, can be used for lesions limited to one area of
the body [33]. The only common guideline is to initiate treat-
ment of PV or PF, with corticosteroids until the disease is
controlled. Once a clinical response is observed, the dose of
systemic corticosteroids can be tapered and eventually discon-
tinued [34, 35]. However, there are patients, in whom the
disease becomes exacerbated as the dose of prednisone is
tapered or do not respond to GC treatment, suggesting GC
resistance. The advances in the understanding of the pathogen-
esis of the disease and the development of new therapies
decreased the mortality rate from 60% to 90% to about 10%
[22, 35, 36]. B cell-directed therapy using anti-CD20 antibody
rituximab directly interferes with pathogenic autoantibodies
and induces rapid clinical remission and long-term control in
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difficult to treat pemphigus. Recent studies have demonstrated
that low dose of rituximab is effective and safe although
relapses may occur, mostly at the end of the second year of
treatment [37]. However, cost-effectiveness studies with a long
follow-up are required to determine the proper dosage of this
expensive drug in pemphigus [38].
Studies on GC sensitivity in pemphigus patients are lack-
ing; in the present study, we observed no difference in lym-
phocyte proliferation in basal condition and also in the dose
that caused a 50% inhibition of cell proliferation (IC50) be-
tween controls and pemphigus patients. Since the binding
assay is more straightforward than the GC-mediated inhibition
of mitogen stimulated PBMC proliferation, we also used this
method for the prediction of GC resistance in patients with
pemphigus. These patients showed a higher Kd compared to
normal subjects, which denotes diminished GR affinity, indi-
cating GC resistance. We also evaluated the number of bind-
ing sites (Bmax), which values were also significantly higher
than controls. These results would suggest a compensatory
increase in the number of GC binding sites in order to over-
come the GR resistance in pemphigus. Since binding assays
evaluate only the GRα isoform, which is the classic ligand-
binding protein for GC, we can not rule out an overexpression
of GRβ inducing steroid insensitivity in pemphigus, as well
established in GC resistant patients with asthma, rheumatoid
arthritis and ulcerative colitis [29, 30, 39].
Studies have suggested that the overexpression of GRβ in
inflammatory diseases would be a consequence of the
inflammation more than a constitutional characteristic contrib-
uting to the development of the disease [40, 41]. Interestingly,
many other GC alterations can be reversible in culture but
sustained with cytokine co-incubation, suggesting that cytokine
secretion may contribute to the acquired GR defect found in
asthma steroid resistant [23]. In addition, while pemphigus is
an antibody mediated disease, the role of T cells in its patho-
genesis is being increasingly recognized [14, 42]. Therefore,
increased production of cytokines can be associated not only
with pemphigus pathogenesis but also can represent another
possible mechanism of GC resistance in pemphigus. Therefore,
in the present study, cytokine profile was also studied in order
to better understand the mechanisms underlying the GC resis-
tance in patients with pemphigus.
PBMC from pemphigus patients showed a higher produc-
tion of TNF-α—a proinflammatory cytokine—than controls,
in basal and after Con-A stimulation. In addition, TNF-α
secretion was significantly inhibited by low dose of DEX in
controls and remained elevated in pemphigus patients even
after high doses of DEX. Similar result was observed with
another proinflammatory cytokine—IL-6 -, which levels
remained elevated in the medium culture from PBMC of
pemphigus patients even after high doses of DEX. On the
other hand, no differences were observed in IL-8 and IL-10
production neither in basal nor in stimulated conditions in
pemphigus patients. Thus, proinflammatory cytokines were
only partially inhibited in patients with pemphigus. These
findings might reflect a predominance of Th1 cells and suggest
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that proinflammatory cytokines might play a role in the mech-
anism of GC resistance in pemphigus patients.
Few studies have been undertaken to measure serum cyto-
kine levels in patients with pemphigus [14, 42, 43]. In these
studies, while IL-6 and TNF-α levels were increased, low to
undetectable levels of IL-8 and IFN-γwere found in serum of
pemphigus patients. Our data, using a different approach, such
as the basal, mitogen-stimulated proliferation and the DEX
mediated inhibition of Con-A stimulated PBMC cytokine
secretion in culture medium, reinforce those previous studies.
In addition, increased expression of IL-6 and TNF-α around
the blistering process of pemphigus has also been reported and
could play a mediator role in pemphigus lesions by increasing
epithelial damage [44]. More recently, the presence of TNF-α,
IFN-γ, and IL-1 in the inflammatory exudates of lesions and
an expression of proinflammatory cytokines, such as TNF-α
and IL-6, around the blister were demonstrated in pemphigus
patients by in situ hybridization. These inflammatory media-
tors might contribute to tissue injury by their ability to directly
or indirectly induce apoptosis [8, 45]. Overall, as expected, the
cytokine levels decrease in the course of treatment with con-
ventional therapy, which causes general immunosuppression
and elimination of proinflammatory cytokine-producing cells
[46]. Altogether, these evidences suggest that proinflamma-
tory cytokines not only can be involved in the immunopatho-
genesis of pemphigus but also in GC resistance observed in a
subset of pemphigus patients.
In conclusion, we described for the first time, an alteration
on GC sensitivity in untreated pemphigus patients. In addition,
PBMC from pemphigus patients showed a higher production
of proinflammatory cytokines, suggesting that they could play
a role in the immunopathogenesis of pemphigus and also
might be involved in the mechanism of GC resistance and/or
in the maintenance of this phenomenon in pemphigus patients.
The possible impact of GC resistance in a less favorable
outcome regarding frequent partial remission, treatment fail-
ure, relapse, the need for high-dose corticosteroids, and treat-
ment dependence remains to be established.
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